Todd Schlesinger, MD

Todd Schlesinger, MD

Todd E. Schlesinger is a Board-Certified Dermatologist, Dermasurgeon and Cosmetic Dermatologist committed to providing the highest quality professional skin care in a warm, friendly and compassionate environment. Graduating magna cum laude and with Phi Beta Kappa honors from the State University of New York at Buffalo he was accepted to medical school at the State University at Buffalo School of Medicine during his sophomore year in college. During medical school he was inducted into the prestigious medical honor society Alpha Omega Alpha during his junior year. Additionally, Dr. Schlesinger received special honors in anatomy and pathology winning entrance into the Gibson Anatomical Society and the Pathology Honor Society. As a recipient of a National Cancer Institute Fellowship at the internationally recognized Roswell Park Cancer Center he earned the opportunity to work with globally acknowledged dermasurgeons in the field of skin cancer resection. Following his training path, he completed his internship and dermatology residency at the world-renowned Cleveland Clinic Foundation, where he authored multiple publications and posters presented at national meetings.

After residency, Dr. Schlesinger completed the requisite training and testing to become a Fellow of the American Society for Mohs Surgery and has trained in dermatologic surgery at the Scripps Clinic in La Jolla, California. The completion of this training has enhanced his reputation of one of the most formidable Mohs surgeons in the low country. Board certified by the American Board of Dermatology, and a fellow of the American Academy of Dermatology, American Society for Dermatologic Surgery, and the American Society for Laser Medicine and Surgery he continues to further his education. Additionally, he is a member of the American Society of Cosmetic Dermatology & Aesthetic Surgery and the American College of Phlebology, a member of the Journal for Clinical and Aesthetic Dermatology’s (JCAD) Editorial Board, and a member of the Digital Editorial Board for CUTIS.

Playing an active role as an advocate for patients and for the betterment of medicine as a whole, he continues to contribute his time to many types of research and development. As a member of the Board of Trustees of the South Carolina Medical Association, an organization representing a large percentage of physicians in the state, he stays abreast of many medical issues in the dermatology field and continues to campaign for the medical community and lay public. Actively involved in organized dermatology, Dr. Schlesinger is the current President of the Charleston County Medical Society, Dr. Schlesinger served as President of the South Carolina Dermatological Association in 2007-2008, a leadership role which included trips to the statehouse in Columbia to educate and lobby for better healthcare coverage in the dermatological field. Working with the American Academy of Dermatology, he served on the national pay for performance work group helping to iron out guidelines for dermatology. With the American Society for Laser Medicine and Surgery, Dr. Schlesinger served on the Constitution and Bylaws Committee, helping to improve the organization of the society.

Dr. Schlesinger was recognized as an alumni recipient of the Cleveland Clinic 2007 Innovator Award. This honor was bestowed upon him for his commitment to collaborate with the Cleveland Clinic Foundation to bring new technology to patients worldwide for his work with neutraceuticals for skin rejuvenation. He lectures regularly for national pharmaceutical and device manufacturers and regularly appears on local television programs and as a Guest or Contributing Author in various magazines discussing the many aspects of professional skin care.

In private practice since 1998, he has extensive experience in all aspects of laser and light-based therapies, having worked with many of these technologies since they were introduced. As founder of the Clinical Research Center of the Carolinas, he actively participates in clinical trials of new and existing therapies and devices.

During his career, Dr. Schlesinger earned an expired acknowledgement as a Clinical Assistant Professor in the Department of Dermatology at the Medical University of South Carolina, when he assisted in the teaching of dermatology residents during their educational instruction in skin cancer surgery by supervising a clinic one-half day every other week at the Charleston Veteran’s Affairs Medical Center. As the Director of the mentoring program at his private practice, Dr. Schlesinger also supervises the formal or informal education of many types of students including participants in the Physician Assistant Program and Family Medicine Residency Program at MUSC, estheticians and medical students.

Dr. Schlesinger is a huge advocate in giving back to the community. He can often be seen as a participant or organizer of Free Skin Cancer Screenings and Health Care Events. His guidance influences staff, students and patients to promote awareness of health and nutrition for the skin, mind and body. As a private business owner, Dr. Schlesinger’s leadership approach is to donate to numerous local and national charities and to challenge others to do the same. Advances in research and development for many illnesses are often funded by the monetary and in-kind donations of others and his commitment to the betterment of healthcare and the associated industries is his motivation behind this devotion.

Todd Schlesinger, MD
2180 Henry Tecklenburg Dr.
Charleston SC 29414
United States

Important Safety Information

Bellafill® is indicated for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years. Patients who have had a positive reaction to the Bellafill® Skin Test, have a history of severe allergies, have known bovine collagen allergies, are allergic to lidocaine, have bleeding disorders or are prone to thick scar formation and/or excessive scarring should not receive Bellafill®. The safety of Bellafill® for use during pregnancy, breastfeeding, or in patients under 21 has not been established. You may experience temporary swelling, redness, pain, bruising, lumps/bumps, itching, and discoloration at the treatment site. These side effects are usually transient and typically resolve within 1–7 days. You may experience lumps/bumps/papules that may occur more than one month after injection and that may persist. Less common side effects include rash and itching more than 48 hours after treatment, persistent swelling or redness, lumps/bumps, acne, and increased sensitivity at treatment sites. Infrequently, granulomas may occur and may be treated by your licensed physician provider. Be sure to call your licensed provider immediately if you notice any unusual skin reactions around the treatment area. Based on the 5-year Post-Approval Study on nasolabial folds with 1,008 patients, long-term safety of Bellafill® for up to 5 years has been established.

This product is certified as a medical device in the European Union under the Medical Device Directive 93/42/EEC by SGS CE0120, exclusively for the indication of autologous fat transfer. Other non-medical uses ascribed to this device such as aesthetic body contouring are not within the scope of CE certification, and users should be aware product performance and/or safety has not been evaluated by SGS for those purposes.

Suneva Medical HD PRP
REGULATORY STATUS: FDA-cleared 510(k) Class II medical device. Healeon HD PRP is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of peripheral blood at the patient point of care. The PRP is mixed with autograft and/orallograft bone prior to application to a bony defect for improving handling characteristics. 510(k) number: BK170136

Silhouette Instalift
Silhouette lnstaLift® is indicated for use in mid-face suspension surgery to temporarily fixate the cheek sub-dermis in an elevated position.

The Silhouette InstaLift device should not be used in patients with any known allergy or foreign body sensitivities to plastic/ biomaterial or in situations where internal fixation is otherwise contraindicated, (e.g. infection.) The device should also not be used in patients appearing to have very thin soft tissue of the face in which the implant may be visible or palpable.

Like all procedures of this type there is a possibility of adverse events, although not everybody experiences them. These adverse events include but are not limited to infection, minimal acute inflammatory tissue reaction, pain (which may be temporary or persistent in nature), swelling and edema, transient hematoma or bruising and transient rippling or dimple formation. For further safety or product information, please consult your physician.

For more safety information, please consult with your physician and the patient labeling that can be found by visiting our website
Toll-free call (U.S. & Canada): 844-Bellafill (844-235-5234).
Local calls: 858-550-9999. International calls: ++ 858-550-9999.